COCH Valuation

Envoy Medical Inc

Add to Watchlist

Advanced Chart

0.721

+0.024(3.442%)1D

COCH Relative Valuation

COCH's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, COCH is overvalued; if below, it's undervalued.

Historical Valuation

Envoy Medical Inc (COCH) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -1.86. The fair price of Envoy Medical Inc (COCH) is between NaN to NaN according to relative valuation methord.

Relative Value

Fair Zone

NaN-NaN

Current Price：0.72

Fair

-0.66

Trailing

Forward

0.00

EV/EBITDA

Envoy Medical Inc. (COCH) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -1.28. The thresholds are as follows: Strongly Undervalued below -5.41, Undervalued between -5.41 and -3.35, Fairly Valued between 0.78 and -3.35, Overvalued between 0.78 and 2.84, and Strongly Overvalued above 2.84. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-0.79

EV/EBIT

Envoy Medical Inc. (COCH) has a current EV/EBIT of -0.79. The 5-year average EV/EBIT is -2.03. The thresholds are as follows: Strongly Undervalued below -5.92, Undervalued between -5.92 and -3.97, Fairly Valued between -0.09 and -3.97, Overvalued between -0.09 and 1.86, and Strongly Overvalued above 1.86. The current Forward EV/EBIT of -0.79 falls within the Historic Trend Line -Fairly Valued range.

102.92

Envoy Medical Inc. (COCH) has a current PS of 102.92. The 5-year average PS is 105.76. The thresholds are as follows: Strongly Undervalued below -85.34, Undervalued between -85.34 and 10.21, Fairly Valued between 201.31 and 10.21, Overvalued between 201.31 and 296.86, and Strongly Overvalued above 296.86. The current Forward PS of 102.92 falls within the Historic Trend Line -Fairly Valued range.

-0.72

P/OCF

Envoy Medical Inc. (COCH) has a current P/OCF of -0.72. The 5-year average P/OCF is -1.35. The thresholds are as follows: Strongly Undervalued below -4.18, Undervalued between -4.18 and -2.76, Fairly Valued between 0.07 and -2.76, Overvalued between 0.07 and 1.49, and Strongly Overvalued above 1.49. The current Forward P/OCF of -0.72 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

Envoy Medical Inc. (COCH) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/FCF of 0.00 falls within the Strongly Undervalued range.

Envoy Medical Inc (COCH) has a current Price-to-Book (P/B) ratio of -2.28. Compared to its 3-year average P/B ratio of -6.87 , the current P/B ratio is approximately -66.83% higher. Relative to its 5-year average P/B ratio of -6.27, the current P/B ratio is about -63.65% higher. Envoy Medical Inc (COCH) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -52.36%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -52.36% , the current FCF yield is about -100.00% lower.

-2.28

P/B

Median3y

-6.87

Median5y

-6.27

-85.10

FCF Yield

Median3y

-52.36

Median5y

-52.36

Competitors Valuation Multiple

The average P/S ratio for COCH's competitors is 0.00, providing a benchmark for relative valuation. Envoy Medical Inc Corp (COCH) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of -25.00%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Nexalin Technology Inc

Firefly Neuroscience Inc

Citius Pharmaceuticals Inc

Vicarious Surgical Inc

Loss

16.11M

Performance Decomposition

Market capitalization of COCH decreased by 68.37% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -10.64K to -15.43K.

The secondary factor is the Revenue Growth, contributed -25.00%to the performance.

Overall, the performance of COCH in the past 1 year is driven by Margin Expansion. Which is more sustainable.

-25.00%

56.00K → 42.00K

Revenue Growth

45.01%

-10.64K → -15.43K

Margin Expansion

-88.38%

-4.55 → -0.53

P/E Change

-68.37%